Final Announcement | This Friday
Is RMST the future of survival analysis? If you're still relying on hazard ratios, it may be time to rethink.
For decades, the hazard ratio (HR) has been the default tool in survival analysis.
But:
- What happens when proportional hazards doesn't hold?
- How do we interpret HR clinically?
- Are we missing a more interpretable and robust alternative?
Join us for a WTASA short course with Prof. Lu Tian (Stanford University):
π₯ Beyond Hazard Ratios: RMST in Clinical Trial Design
π
April 17, 2026
β° 2β5 PM (Central Time)
π» Online
This course introduces Restricted Mean Survival Time (RMST) - an increasingly important framework for:
β Clinically interpretable treatment effect
β Robust analysis under non-proportional hazards
β Modern clinical trial design
π Topics include:
- Limitations of HR
- RMST fundamentals
- Trial design with RMST
- Non-inferiority
- Competing risks
- Duration of response
π΅ Registration: $20
π https://lnkd.in/gbFzYbcE
We anticipate a highly engaged audience across biostatistics, oncology, and clinical research.
Final call - we look forward to seeing you there.
π Can't make it live? No problem - a recording and slides will be available to all registered participants.
#Statistics #Biostatistics #ClinicalTrials #SurvivalAnalysis #RMST #Oncology #DataScience #ASA
------------------------------
Haitao Pan
Associate Professor
St. Jude Children's Research Hospital
------------------------------